Menu

Recent Interviews

Heye Daun, President and CEO, Osino Resources Corp.

Heye Daun
President and CEO | Osino Resources Corp.
Suite 810 – 789 West Pender Street, V6C 1H2 Vancouver (CAN)

jbecker@osinoresources.com

Interview Osino Resources: "The market has not yet realized how fast we are advancing Twin Hills."


Bradley Rourke, President, CEO and Director, Scottie Resources Corp.

Bradley Rourke
President, CEO and Director | Scottie Resources Corp.
905 - 1111 West Hastings Street, V6E 2J3 Vancouver (CAN)

info@scottieresources.com

+1 250-877-9902

Interview Scottie Resources: Exciting Story in the Golden Triangle


Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


19. March 2020 | 11:25 CET

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

  • Biotechnology
Photo credits: pixabay.com

People around the world are worried about the extent of the consequences associated with the spread of the corona virus COVID-19, and politicians and the economy are called upon to deal with the situation appropriately so that the loss of life and financial damage to the citizens can be kept to a minimum. Medical experts are now working intensively to ensure that active substances for prevention and therapy are tested and made ready for the market.

time to read: 2 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Development of a vaccine

The German biotech company BioNTech is working with renowned partners in China, Europe and the USA to develop a vaccine for the immunization and prevention of COVID-19 infections. A clinical trial is scheduled to start as early as April 2020. The company is pursuing the goal of making a vaccine available worldwide as quickly as possible. For this reason, BioNTech says it is "in close contact with various regulatory and scientific authorities around the world and is in ongoing discussions with other research institutions."

Investigational compound for corona viruses

US company Gilead Science is also working with global health authorities to counteract the outbreak of the new type of COVID-19 by using the investigational compound Remdesivir. Remdesivir has shown activity against MERS and SARS in animal studies, which are also corona viruses and show structural similarities to COVID-19. Since it is an experimental drug that has only been used in a small number of patients with COVID-19, Gilead is still in the early stages of development with Remdesivir.

Multi-billion growth market IVF

The Australian company Memphasys focuses on the in vitro fertilisation (IVF) market for humans, which, according to Allied Market Research, currently has a global volume of USD 13.7 billion and is expected to grow to USD 26.4 billion by 2026. Memphasys focuses on the key element of a successful pregnancy for parents who want to have children: the quality of the used sperm. Sperm quality is declining worldwide, with one in three men over the age of 40 having problems with sperm fertility. About half of all infertility cases have poor sperm as an identifying factor.

Separation of sperm

Memphasys has developed an innovative device to separate and select sperm more quickly and effectively than current methods. The device called FELIX uses electric fields and membranes to sort the sperm according to quality and size. According to Alison Coutts, CEO of Memphasys, the better sperm has a greater net negative charge compared with faulty specimens.

Launching in Q3 2020

The company's next step is to support physicians in less regulated markets so that they can use the device commercially after completion of verification and validation, which is expected in mid 2020. At the same time, the company is working to obtain marketing approval from key regulatory authorities in Australia, the United States and Europe. While approval is a multi-year and costly process, Memphasys plans to sell early in countries with lighter regulation. These initial markets could include Japan, India, New Zealand and Canada.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

10. May 2021 | 09:14 CET | by Stefan Feulner

CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!

  • Biotechnology

The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.

Read

28. April 2021 | 07:04 CET | by Stefan Feulner

CureVac, PsyBio, Evotec - Revolution in the billion-dollar market!

  • Biotechnology

The anxiety and limitations associated with the coronavirus pose major challenges for people suffering from depression. Officially, around 350 million people worldwide live with depression, but the number of unreported cases is significantly higher. At the moment, the number one cause of the disease is only combated with antidepressants; there are hardly any alternative treatment methods without severe side effects. A completely new field is currently emerging that could completely eclipse existing drugs, with incredible potential for the young companies.

Read

20. April 2021 | 06:50 CET | by Nico Popp

CureVac, BioNTech, PsyBio: Yesterday's game changers - and tomorrow's?

  • Biotechnology

Vaccines against the coronavirus are changing everything. People who sat anxiously at home just a few weeks ago now dare to socialize again after their injection. Even if contact restrictions still apply - the feeling of being alive is different after the vaccination. German vaccine manufacturers, in particular, have used innovative mRNA technology to create vaccines that are largely scandal-free - and offer good protection. In the slipstream, new, innovative companies are already preparing to bring the next game changers to market. For investors, this can be a rewarding environment.

Read